Killer cell lectin-like receptor subfamily G member 1 (KLRG1) has been found on human memory T lymphocytes. However, the roles of KLRG1 on human T cells especially in tumor microenvironment have not been fully understood. 
INtrODUctION
KLRG1 is a co-inhibitory receptor belonging to inhibitory killer cell lectin-like receptors on NK cells and antigen-experienced human T cells [1, 2] . KLRG1 was thought to be a senescent marker for human T cells with poor proliferation and impaired clonal expansion after stimulation [3] . It has been reported that the expression of KLRG1 on human CD8 + T cells was elevated in the condition of virus infection, which may contribute to increased morbidity of infectious diseases [1, 4] . However, the expression and role of KLRG1 on human T cells in the tumor microenvironment remain to be well addressed.
Programmed cell death protein 1 (PD-1, CD279) has been reported to be involved in the anergy and exhaustion of T cells [5, 6] . T-cell inhibitory receptor Tim-3 (T-cell immunoglobulin and mucin-domain containing-3) was reported to be an immune checkpoint receptor [7] . Tim-3 was also considered as a surface marker for T cell exhaustion [8, 9] .
Ectonucleotidases play a pivotal role in the regulation of purinergic signaling pathway. CD39 (ectonucleoside triphosphate diphosphohydrolase 1, E-NTPDase1) can convert ATP into AMP, which is subsequently dephosphorylated into adenosine by CD73 (ecto-50-nucleotidase, Ecto50NTase) [10, 11] . The metabolic pathway shifts the ATP-driven proinflammatory environment to adenosine-induced anti-inflammatory status [10] . It tilts the balance towards immunosuppressive microenvironment [11] , favoring tumor immune-evasion [12] . Extracellular accumulation of adenosine can lead to T cell inhibition and anergy [13, 14] , contributing to tumor progression [15] . Antibodies targeting CD73 and CD39 exhibited proven efficacy in mouse tumor models [16] . CD73-adenosine pathway played a major role in the immune evasion and high CD73 expression predicted poor outcome of ovarian cancer patients [17] .
MicroRNAs (miRNAs) are involved in the post-transcriptional regulation through binding to 3' untranslated regions (UTRs) and coding region (CDS) of target mRNAs [18] [19] [20] . miRNAs are important functional modulators for T cells [21] . C-terminal binding protein-2 (CtBP2) is a transcriptional co-repressor gene involved in tumorigenesis and tumor progression [22, 23] . We have recently demonstrated that miRNA-101 increased cancer cell stemness by repressing CtBP2 [22] .
In this study, we examined the roles of KLRG1 in human T cells and the underlying mechanism, especially in the tumor microenvironment.
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KlrG1
+ t cells enriched in tumor microenvironment
We set out to check the expression level of KLRG1 on human T cells. We isolated peripheral blood mononuclear cells (PBMC) from healthy donors and checked KLRG1 expression by flow cytometry. It showed that CD3 + T cells expressed limited KLRG1 in healthy donors ( Figure 1A ). In contrast, T cells isolated from ovarian cancer and colitis expressed high level of KLRG1 ( Figure 1A ). We also found KLRG1 expression significantly increased in both CD4
+ and CD8 + T cells in colon cancer, colitis and ovarian cancer ( Figure 1B, 1C) . Immunofluorescence cell staining confirmed the higher level of KLRG1 expression on CD3 + T cells in colon cancer tissue compared with the expression in colon tissue from patients received colectomy after trauma ( Figure 1D ). Similar results were observed in colitis and ovarian cancer tissues (data not shown). The results indicated that human T cells in tumor microenvironment expressed increased level of KLRG1.
KlrG1
+ t cells exhibited senescent characteristics
We next investigated the characteristics of KLRG1 We examined whether KLRG1 + T cells could keep proliferative ability. Our results showed KLRG1 + T cells barely expressed proliferative marker Ki67 ( Figure 2B ). Our group have recently reported human memory T cells highly express epigenetic repressor EZH2 [24] , which could be used as an alternative proliferative marker. Similarly, we found KLRG1 + T cells expressed limited EZH2 ( Figure 2B ), which indicated KLRG1 + T cells lost the proliferative capacity. To further confirm the limited proliferation of KLRG1 + T cells, we performed functional study via proliferation assay to compare FACS sorted KLRG1 positive and negative T cells. As shown in Figure 2C , KLRG1 − T cells proliferated efficiently after challenged with anti-CD3 and anti-CD28 antibodies while KLRG1 + cells showed poorly proliferative potential. Additionally, KLRG1 + T cells incorporated significantly less thymidine compared with KLRG1 − T cells ( Figure 2D ). It was recently reported that KLRG1 impairs T cell response in HCV infection via p16 and p27 pathways [25] . Interestingly, our results showed no significant differences of cyclin-dependent kinase inhibitors between KLRG1 positive and negative populations (Supplementary Figure S1A) . Similary, we found no significant differences of cyclin-related genes (Supplementary Figure S1B) .
To exclude the possibility that KLRG1 + T cells are functionally exhausted, we performed flow cytometry and found that KLRG1 + T cells were distinct from PD-1 or Tim-3 positive populations ( Figure 2E ). Further analysis showed no significant differences of Bcl-2 and Bcl-XL expression between KLRG1 + and KLRG1 − CD8 + T cells (Supplementary Figure S1C) , indicating that KLRG1 + T cells were not undergoing apoptosis. These results indicated that human KLRG1 + T cells were terminally differentiated memory cells with senescent characteristics and limited proliferative potential.
KlrG1 dampened t cell effector function
We have shown that human KLRG1 + T cells exhibited senescent phenotype. Next we examined the effector function of KLRG1 + T cells. Flow cytometry analysis showed that KLRG1 + CD4 T cells barely produced IL-17 and KLRG1 + CD8 T cells expressed limited effector cytokines IFN-γ, Granzyme B and TNF-α ( Figure 3A ). We FACS sorted KLRG1 positive and negative T cells from PBMC and performed RT-PCR analysis. Our results showed significantly less expression of IL-2 and IL-17 in KLRG1 + CD4 T cells ( Figure 3B ) and IFN-γ and TNF-α in KLRG1 + CD8 T cells compared with their KLRG1
− counterparts ( Figure 3C ). Thus, our results indicated that KLRG1 dampened T cell effector function.
KlrG1 + t cells contributed to the immunosuppressive network in tumor microenvironment
As shown above, KLRG1 + T cells have impaired effector cytokine production. Next we investigated the production of pro-inflammatory cytokines. We found KLRG1 + T cells secreted significantly higher levels of IL-1b, IL-6 and IL-8 than KLRG1
− T cells by RT-PCR analysis ( Figure 4A ). Furthermore, flow cytometry analysis discovered more Foxp3 positive cells in KLRG1 + CD4 T cell population ( Figure 4B ). Expression of ectonucleotidases CD73 and CD39 was reported to be immunosuppressive and the subsequent production of adenosine contributed to impaired anti-tumor T cell response [10, 11, 26] . Interestingly, our results uncovered that KLRG1 + memory CD8 T cells highly expressed CD73 and CD39 ( Figure 4C and 4D) . These results indicated that human KLRG1 + T cells possessed immune-suppressive function and pro-inflammatory potential, which may contribute to the immune-suppressive network in the tumor microenvironment.
mirNA-101/ctbP2 pathway involved in KlrG1-restricted antitumor immunity
Then we investigated the underlying mechanism regulating KLRG1 + T cells. miRNAs are known to be critical for T cell regulation. Our results showed diminished expression of several miRNAs in KLRG1 + CD8 T cells compared with expression in KLRG1 − counterparts by RT-PCR analysis ( Figure 5A ). Among these reduced miRNAs, we focused on miRNA-101. We have reported that miRNA-101 increased cancer cell stemness by repressing the corepressor gene C-terminal binding protein-2 (CtBP2) [22] . In line with our previous findings, KLRG1
+ CD8 T cells exhibited significantly elevated expression of CtBP2 ( Figure 5B ). Taken together, our results indicated miRNA-101 might contribute to impaired antitumor immunity restricted by KLRG1 through repressing CtBP2.
DIscUssION
KLRG1 is considered as a senescent marker for human T cells [3] . Consistent with the previous reports, our results showed that human KLRG1 + T cells exhibited poor proliferative potential. And KLRG1 expression was confined to memory population, indicating KLRG1 + T cells were antigen-experienced memory cells. Furthermore, KLRG1 + T cells were distinct from functionally exhausted or anergy populations. It was reported that mouse KLRG1 high CD8 T cells expressed lower levels of both anti-apoptotic Bcl-2 and pro-apoptotic Bim compared with KLRG1 low counterparts after LCMV infection [27] . However, our results exhibited no significant differences of Bcl-2 and Bcl-XL expression between human KLRG1 + and KLRG1
− CD8 T cells, suggesting KLRG1 + T cells presented no apoptosis preference. The results indicated KLRG1 + T cells were terminally differentiated memory T cells which haven't entered the apoptotic stage.
Human CD8 T cells from virus infection highly expressed KLRG1 which may be related with the increased incidence of infectious diseases [1, 4] . We found elevated KLRG1 expression on T cells from patients with cancer and autoimmune disease. It suggested that KLRG1 might contribute to the T cell dysfunction in pathological conditions. Our data suggested that except for the poor proliferative capacity, KLRG1 resulted in diminished production of effector cytokines and meanwhile elevated production of pro-inflammatory cytokines of T cells. It has Ectonucleotidases CD39 and CD73 were reported to impair immune system by switching from proinflammatory to the anti-inflammatory status [10] . The subsequent production of adenosine contributed to tumor progression by impairing T cell antitumor immunity [26] . Interestingly, we found significantly higher levels of both CD39 and CD73 expression on KLRG1 [14, 29, 30] . The results suggested human KLRG1 + T cells might be involved in the dysfunction of T cell antitumor immune response by regulating metabolic pathway through ectonucleotidases.
miRNAs have been reported to be an important modulator in T cell exhaustion in HIV infection [31] . However, little is known about the effect of miRNAs on human T cell senescence. In this work, we demonstrated that KLRG1 + CD8 T cells expressed lower levels of miR-101, miR-155 and miR-200b. miR-155 has been demonstrated to be required for effector CD8 T cell responses against infection and cancer [32] . We have previously reported that miRNA-101 increased cancer cell stemness by repressing CtBP2 [22] . Similarly, our data here exhibited elevated CtBP2 expression in KLRG1 + CD8 T cells. Moreover, CtBP2 has been reported to be a repressor of T cell cytokine production [33, 34] , which could lead to the diminished production of effector cytokine of human KLRG1 + T cells. Thus, we hypothesized that declined miR-101 expression in human KLRG1 + T cells leaded to elevated expression of co-repressor CtBP2, which subsequently suppressed the effector cytokine production of KLRG1 + T cells, resulting in impaired T cell antitumor immunity in tumor microenvironment.
Taken together, our work suggested that KLRG1 was actively participating in the restricted T cell antitumor immunity by the following five aspects: 1) poor proliferative capacity, 2) diminished production of effector cytokines, 3) elevated production of pro-inflammatory cytokines, 4) immunosuppressive potential and 5) increased adenosine production by ectonucleotidase. And miR-101/CtBP2 pathway might be involved in the impaired antitumor immunity restricted by KLRG1. Therefore, our work suggested that repressing KLRG1 could be a novel therapeutics against tumor. 
Fluorescence activated cell sorting (FAcs) and flow cytometry analysis
For cytokine detection, cells were stimulated with phorbol myristate acetate (50 ng/mL; Sigma-Aldrich), ionomycin (1 µM; Sigma-Aldrich) for 4 hours with protein transport inhibitor (GolgiPlug 1 µl/ml, GolgiStop 2/3 µl/ml; BD Bioscience) in complete medium (CM) before staining. Cells were first stained extracellularly with specific antibodies against human CD3, CD4, CD8, CD45RA, CD45RO (BD Bioscience), then were fixed and permeabilized with Fixation/Permeabilization solution (eBioscience), and finally were stained intracellularly with anti-IL-2, anti-IL-17, anti-tumor necrosis factor-α (TNF-α), anti-interferon-γ (IFN-γ), anti-Granzyme B, anti-Ki67 and anti-EZH2 (BD Biosciences). Samples were acquired on flow cytometry (LSR II; Becton Dickinson) and data were analyzed with DIVA software (BD Biosciences) [35] . The gating strategy was shown in Supplementary Figure S2 . KLRG1 + and KLRG1 − T cells were purified and sorted with FACSAria cell sorter (Becton Dickinson).
[ 3 h] thymidine incorporation assay
The Thymidine incorporation assay was done as described [6, 36] . Briefly, CD3 T cells were seeded into 96-well plate with serial dilution and stimulated with 1:1 irradiated human PBMC, 2.5 µg/ml rhαCD3 and 1.25 µg/ ml rhαCD28 for 2 days in 37 o C incubator in 100 µl CM. . For miRNA detection, relative expression was normalized to U6. Detail of primers is summarized in Supplementary Table S1 .
Immunofluorescent staining
Frozen sections from colitis, ovarian cancer, colon cancer and traumatic colon were fixed with 2% paraformaldehyde and permeabilized for 1 hour at RT with PBS with 0.1% Triton X-100. Slides were incubated with primary antibodies against KLRG1 (Santa Cruz Biotechnology, sc-23598, 1:100) or CD3 (Dako, A0452, 1:100) for overnight at 4 o C after blocking with 10% goat serum. After washing away primary antibodies, slides were incubated with fluorescence-conjugated secondary antibodies for 1 hour at RT. Then staining was examined under fluorescent microscope (Leica DM5000 B).
statistics
Dependent on data distribution and experimental design, paired or unpaired Student t test and MannWhitney U tests were used. All analyses were done by using SAS 9.3 software. The results were considered statistically significant when p value is less than 0.05. 
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